QR kód

Multiple autologous tumor-infiltrating lymphocyte (LM103 infusion) therapy combined with immune checkpoint inhibitor induces repeated tumor regression in a patient with aggressive mucosal melanoma: a case report and literature review

Tumor-infiltrating lymphocyte (TIL) therapy was approved as a one-dose treatment indicated for melanoma patients who have progressed on anti-PD-1 therapy. However, the majority of patients show only short-duration responses, highlighting the urgent need to explore multiple cycles of TIL therapy and...

Celý popis

Uloženo v:
Hlavní autoři: Fenge Li, Yue Xu, Yupeng Wang, Ning Mu, Mei Liu, Weihong Feng, Yongming Xue, Shengnan Wu, Xinyi Wang, Gregory Lizee, Chunhua Ma
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2026-04-01
Edice:Frontiers in Oncology
Témata:
clinical response
cytokine secretion
immune monitoring
multiple TIL therapy
tumor-infiltrating lymphocytes
On-line přístup:https://www.frontiersin.org/articles/10.3389/fonc.2026.1789442/full
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky